Long‐term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: Phase 3 open‐label extension study
Allergy · 2025-02 · 80 (2) · 545-556
DOI: 10.1111/all.16351 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Allergy, online erschienen am 07.10.2024. Verfasst von Avner Reshef und 14 weiteren Autor:innen. Beteiligte Einrichtung: Allergy, Immunology and Angioedema Center, Barzilai University Hospital, Ashkelon, Israel. Hauptthemen laut MEDLINE: Angioedemas, Hereditary, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CSL Behring.
Abstract (Originalsprache)
Background
Hereditary angioedema (HAE) is a chronic, unpredictable disease. Long‐term prophylactic treatments that offer durable efficacy, safety, and convenience are required to assist patients in achieving complete disease control, per international guidelines. We report an interim analysis of an ongoing phase 3 (VANGUARD) open‐label extension (OLE) study evaluating the long‐term safety and efficacy of garadacimab for HAE prophylaxis.
Methods
Adults and adolescents aged ≥12 years with HAE previously participating in phase 2 and pivotal phase 3 (VANGUARD) studies were rolled over to an OLE, alongside newly enrolled patients. Patients received garadacimab 200 mg subcutaneously, once monthly for ≥12 months. The primary endpoint was treatment‐emergent adverse events (TEAEs) in patients with C1 inhibitor deficiency/dysfunction.
Results
At data cut‐off (February 13, 2023; N = 161), median (interquartile range) exposure was 13.8 months (11.9–16.3). For the primary endpoint, 133/159 patients experienced ≥1 TEAE (524 events), equivalent to 0.23 events/administration and 2.84 events/patient‐year. Garadacimab‐related TEAEs (13% of patients, 52 events) were most commonly injection‐site reactions (ISRs). No deaths occurred. One patient discontinued treatment due to garadacimab‐related moderate ISR. Most TEAEs were mild/moderate; three events were serious (COVID‐19, two events; abdominal HAE attack, one event) and not garadacimab related. No abnormal bleeding, thromboembolic, severe hypersensitivity, or anaphylactic events were observed. Mean HAE attack rate decreased by 95% from the run‐in period; 60% of patients were attack‐free. Almost all patients (93%) rated their response to garadacimab as “good” or “excellent.” Conclusion Garadacimab has a favorable safety profile suitable for long‐term use and provides durable protection against HAE attacks.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Allergy, Immunology and Angioedema Center, Barzilai University Hospital, Ashkelon, Israel.
- Research Solutions of Arizona, Litchfield Park, Arizona, USA.
- Allergy and Immunology Unit, Campbelltown Hospital and Western Sydney University, Sydney, New South Wales, Australia.
- Division of Rheumatology and Clinical Immunology, Department of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong.
- Institute of Allergology, Charité - University Medicine Berlin (joint medical faculty of Free University of Berlin and Humboldt University of Berlin), Berlin, Germany.
- Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany.
ORCID-Profile: Avner Reshef, Connie Hsu, Constance H Katelaris, Philip H Li, Markus Magerl, Keiko Yamagami, Mar Guilarte, Paul K Keith, Jonathan A Bernstein, John-Philip Lawo, Tim J Craig
Förderung
- CSL Behring
Zitieren
APA
Reshef, A., Hsu, C., Katelaris, C. H., Li, P. H., Magerl, M., Yamagami, K., Guilarte, M., Keith, P. K., Bernstein, J. A., Lawo, J. P., Shetty, H., Pollen, M., Wieman, L., Craig, T. J., & VANGUARD Study Group (2025). Long‐term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: Phase 3 open‐label extension study. Allergy, 80(2), 545-556. https://doi.org/10.1111/all.16351
Vancouver
Reshef A, Hsu C, Katelaris CH, Li PH, Magerl M, Yamagami K, et al. Long‐term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: Phase 3 open‐label extension study. Allergy. 2025;80(2):545-556. doi:10.1111/all.16351
BibTeX
@article{Reshef2025,
author = {Reshef, Avner and Hsu, Connie and Katelaris, Constance H and Li, Philip H and Magerl, Markus and Yamagami, Keiko and Guilarte, Mar and Keith, Paul K and Bernstein, Jonathan A and Lawo, John-Philip and Shetty, Harsha and Pollen, Maressa and Wieman, Lolis and Craig, Tim J and VANGUARD Study Group, VANGUARD Study Group},
title = {Long‐term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: Phase 3 open‐label extension study},
journal = {Allergy},
year = {2025},
volume = {80},
number = {2},
pages = {545--556},
doi = {10.1111/all.16351}
}
EUVIMED